t looks like there won’t be any Yelp reviewscolor-coded drugs, or seasteading in the Food and Drug Administration’s future. Instead, President Donald Trump is going with the establishment candidate — and the biotech industry couldn’t be more relieved.

Dr. Scott Gottlieb, a former deputy commissioner at FDA who also has a Wall Street pedigree, is Trump’s nominee to lead the agency, ending months of speculation and consternation among biotech insiders.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that until Scott is formally designated as the nominee and the Senate approves him, it is too early to celebrate. While this potential choice counts as a pleasant surprise, the President always seems to have ‘another surprise’ in the wings. Senate confirmation first then pop the corks, assuming, of course, that now the nomination is set.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.